Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
Yuki Takeyasu, Tatsuya Yoshida, Ryota Shibaki, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yuichiro Ohe
Topics & Concepts
PembrolizumabMedicineInternal medicineHazard ratioLung cancerOncologyConfidence intervalPD-L1CancerImmunotherapyCancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical ImagingPeptidase Inhibition and Analysis